Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

BACKGROUND: Folate binding protein(FBP) is an immunogenic protein over-expressed in endometrial(EC) and ovarian cancer(OC). We are conducting a phase I/IIa trial of E39 (GALE 301)+GM-CSF, an HLA-A2-restricted, FBP-derived peptide vaccine to prevent recurrences in disease-free EC and OC patients. Thi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Jackson, Doreen O., Byrd, Kevin, Vreeland, Timothy J., Hale, Diane F., Herbert, Garth S., Greene, Julia M., Schneble, Erika J., Berry, John S., Trappey, Alfred F., Travis Clifton, Guy, Hardin, Mark O., Martin, Jonathan, Elkas, John C., Conrads, Thomas P., Darcy, Kathleen M., Hamilton, Chad A., Maxwell, George L., Peoples, George E.
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2016
Fag:
Clinical Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5362533/
https://ncbi.nlm.nih.gov/pubmed/27852036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13305
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker